24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

Condition(s) targeted: Type 2 Diabetes Mellitus

Intervention: Lixisenatide (AVE0010) (Drug); Placebo (Drug); Insulin glargine (Drug); Pen auto-injector (Device); Metformin (Drug); Thiazolidinedione (TZD) (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Sanofi

Official(s) and/or principal investigator(s):
Clinical Study Operations, Study Director, Affiliation: Sanofi

The purpose of the study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to insulin glargine and metformin with or without thiazolidinediones (TZDs), over a period of 24 weeks of treatment. The primary objective is to assess the effects of lixisenatide in comparison to placebo, when added to insulin glargine and metformin, on glycemic control in terms of glycosylated hemoglobin (HbA1c) reduction (absolute change) at Week 24. The secondary objectives are to assess the effects of lixisenatide on the percentage of patients reaching HbA1c less than (<) 7 percent (%) and less than or equal to (<=) 6. 5%, plasma glucose (fasting, postprandial during a standardized meal challenge test, 7-point self monitored profiles), body weight, insulin glargine doses, to evaluate safety and tolerability (including anti-lixisenatide antibody assessment), and to assess the impact on treatment satisfaction using the Diabetes Treatment Satisfaction Questionnaire (state) (DTSQs) in the participating countries where it is validated.

Official title: A Randomized, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Double-blind Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine and Metformin

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

Secondary outcome:

Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) at Week 24

Change From Baseline in Glucose Excursion at Week 24

Change From Baseline in Average 7-Point Self Monitored Plasma Glucose (SMPG) Profile at Week 24

Change From Baseline in Body Weight at Week 24

Change From Baseline in Average Insulin Glargine Daily Dose at Week 24

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24

Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24

Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24

Percentage of Patients Requiring Rescue Therapy During the Double-blind Period

Change From Baseline in Treatment Satisfaction Score (Sum of Items 1, 4, 5, 6, 7 and 8 of DTSQ) at Week 24

Detailed description: The study comprises 3 periods:

- An up to 14-week screening period, which includes an up to 2-week screening phase and a

12-week run-in phase with introduction and titration of insulin glargine on top of metformin +/-TZDs.

- At the end of the run-in phase, patients whose HbA1c (centralized assay) is greater

than or equal to (>=) 7% and less than or equal to (<=) 9% and whose mean fasting self-monitored plasma glucose (SMPG) calculated from the self measurements for the 7

days prior to Visit 12 (Week - 1) is <=140 milligram per deciliter (mg/dL) (7. 8

millimole per liter [mmol/L]), would enter a 24-week double-blind randomized treatment period comparing lixisenatide to placebo (on top of insulin glargine + metformin +/- TZDs).

- A 3-day safety follow up period.

Maximum duration is of 39 weeks +/- 7 days.

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion criteria:

- Type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit,

insufficiently controlled with insulin glargine and metformin Exclusion criteria:

- HbA1c <7% or greater than (>)10% at screening

- At the time of screening age < legal age of majority

- Pregnant or breastfeeding women or women of childbearing potential with no effective

contraceptive method

- Type 1 diabetes mellitus

- Metformin not at a stable dose of at least 1. 5 gram per day for at least 3 months

prior to the screening visit

- Use of oral or injectable antidiabetic or hypoglycemic agents other than metformin,

sulfonylurea (SU) and TZDs (for example, alpha glucosidase inhibitor, other glucagon like peptide-1 [GLP-1] receptor agonists, dipeptidyl peptidase-IV [DPP-IV] inhibitors, insulin etc.) within 3 months prior to the time of screening, use of weight loss drugs if not at a stable dose for at least 3 months prior to the screening visit

- History of hypoglycemia unawareness

- Body Mass Index (BMI) less than or equal to (<=) 20 kilogram per square meter

(kg/m^2)

- History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy,

stomach/gastric surgery, inflammatory bowel disease, personal or family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (for example, multiple endocrine neoplasia syndromes)

- History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to

screening

- Hemoglobinopathy or hemolytic anemia, blood or plasma products transfusion within 3

months prior to the time of screening

- Within the last 6 months prior to screening: history of myocardial infarction,

stroke, or heart failure requiring hospitalization

- Known history of drug or alcohol abuse within 6 months prior to the time of screening

- Any clinically significant abnormality identified on physical examination, laboratory

tests, electrocardiogram or vital signs at the time of screening that in the judgment of the Investigator or any sub investigator precludes safe completion of the study or constrains efficacy assessment such as active malignant tumor or other major systemic diseases, presence of clinically significant diabetic retinopathy or presence of macular edema likely to require laser treatment within the study period

- Uncontrolled or inadequately controlled hypertension at the time of screening with a

resting systolic or diastolic blood pressure >180 millimeter of mercury (mmHg) or >110 mmHg, respectively

- Laboratory findings at the time of screening: amylase and/or lipase, alanine

aminotransferase >3 times upper limit of the normal (ULN) laboratory range; total bilirubin: >1. 5 times ULN (except in case of Gilbert's syndrome); hemoglobin <11 gram/deciliter and/or neutrophils <1500 per cubic millimeter (mm^3) and/or platelets <100 000/mm^3; positive test for Hepatitis B surface antigen and/or Hepatitis C antibody, positive serum pregnancy test in females of childbearing potential; and calcitonin >=20 picogram per milliliter (pg/mL) (5. 9 picomole per milliliter [pmol/L])

- Patients who are considered by the Investigator or any sub investigator as

inappropriate for this study for any reason (for example, impossibility to meet specific protocol requirements, such as scheduled visits, being able to do self-injections, likelihood of requiring treatment during the screening phase and treatment phase with drugs not permitted by the clinical study protocol, patient being investigator or any sub investigator, pharmacist, study coordinator, other study staff or relative thereof directly involved in the conduct of the protocol etc.)

- Use of systemic glucocorticoids (excluding topical application or inhaled forms) for

one week or more within 3 months prior to the time of screening

- Use of any investigational drug within 3 months prior to screening

- Renal impairment defined with serum creatinine > 1. 4 mg/dL in women and > 1. 5 mg/dL

in men

- History of hypersensitivity to insulin glargine or to any of the excipients

- Clinically relevant history of gastrointestinal disease associated with prolonged

nausea and vomiting, including (but not limited to): gastroparesis, unstable (that is, worsening) and not controlled (that is, prolonged nausea and vomiting) gastroesophageal reflux disease requiring medical treatment, within 6 months prior to the time of screening

- Any previous treatment with lixisenatide (for example, participation in a previous

study with lixisenatide)

- Allergic reaction to any GLP-1 receptor agonist in the past (for example, exenatide,

liraglutide) or to metacresol

- Additional exclusion criteria during or at the end of the run-in phase before

randomization: informed consent withdrawal (patient who was not willing to continue or failed to return), mean fasting SMPG calculated from the self-measurements for the

7 days prior to Visit 12 (Week - 1) was >140 mg/dL (7. 8 mmol/L) and HbA1c measured at

Visit 12 (Week - 1) is <7% or >9%, amylase and/or lipase > 3 times the ULN at Visit 12

(Week - 1), patients with fasting plasma glucose (FPG) above the threshold value

described for rescue (that is, FPG >240 mg/dL [13. 3 mmol/L]), patients with any adverse event, which, by the judgment of the Investigator precludes the inclusion in the double-blind randomized treatment phase, and lack of compliance to protocol or to insulin glargine treatment during the run-in phase

Sanofi-Aventis Investigational Site Number 032204, Buenos Aires, Argentina

Sanofi-Aventis Investigational Site Number 032201, Capital Federal 1425, Argentina

Sanofi-Aventis Investigational Site Number 032205, Capital Federal 1012, Argentina

Sanofi-Aventis Investigational Site Number 032209, Capital Federal C1056ABJ, Argentina

Sanofi-Aventis Investigational Site Number 032211, Corrientes, Argentina

Sanofi-Aventis Investigational Site Number 032202, Parana (E3100BBJ), Argentina

Sanofi-Aventis Investigational Site Number 032203, Rosario 2000, Argentina

Sanofi-Aventis Investigational Site Number 076207, Belem 66073-000, Brazil

Sanofi-Aventis Investigational Site Number 076202, Brasilia 71625-009, Brazil

Sanofi-Aventis Investigational Site Number 076205, Porto Alegre 90035001, Brazil

Sanofi-Aventis Investigational Site Number 076204, Sao Paulo 04024-002, Brazil

Sanofi-Aventis Investigational Site Number 124219, Brampton L6R 3J5, Canada

Sanofi-Aventis Investigational Site Number 124213, Chatham N7L 1C1, Canada

Sanofi-Aventis Investigational Site Number 124208, Chilliwack V2P 4M9, Canada

Sanofi-Aventis Investigational Site Number 124215, Etobicoke M9R 4E1, Canada

Sanofi-Aventis Investigational Site Number 124205, Quebec G1V 4G5, Canada

Sanofi-Aventis Investigational Site Number 124202, Red Deer T4N 6V7, Canada

Sanofi-Aventis Investigational Site Number 124218, Thornhill L4J 8L7, Canada

Sanofi-Aventis Investigational Site Number 124201, Toronto M4R 2G4, Canada

Sanofi-Aventis Investigational Site Number 124207, Toronto M9V 4B4, Canada

Sanofi-Aventis Investigational Site Number 124209, Victoria V8V 4A1, Canada

Sanofi-Aventis Investigational Site Number 124217, Winnipeg R3E 3P4, Canada

Sanofi-Aventis Investigational Site Number 152201, Santiago, Chile

Sanofi-Aventis Investigational Site Number 152202, Santiago 7500010, Chile

Sanofi-Aventis Investigational Site Number 152203, Santiago 7980378, Chile

Sanofi-Aventis Investigational Site Number 152204, Santiago 8360156, Chile

Sanofi-Aventis Investigational Site Number 152205, Santiago 8930211, Chile

Sanofi-Aventis Investigational Site Number 152206, Santiago 8053095, Chile

Sanofi-Aventis Investigational Site Number 170204, Barranquilla, Colombia

Sanofi-Aventis Investigational Site Number 170201, Bogota, Colombia

Sanofi-Aventis Investigational Site Number 170202, Bogota, Colombia

Sanofi-Aventis Investigational Site Number 203202, Hradec Kralove 50005, Czech Republic

Sanofi-Aventis Investigational Site Number 203204, Praha 5 15006, Czech Republic

Sanofi-Aventis Investigational Site Number 208202, Frederiksberg 2000, Denmark

Sanofi-Aventis Investigational Site Number 208201, København Nv 2400, Denmark

Sanofi-Aventis Investigational Site Number 208205, Slagelse 4200, Denmark

Sanofi-Aventis Investigational Site Number 233201, Pärnu 80018, Estonia

Sanofi-Aventis Investigational Site Number 233203, Tallinn 13415, Estonia

Sanofi-Aventis Investigational Site Number 233204, Tartu 50410, Estonia

Sanofi-Aventis Investigational Site Number 233202, Viljandimaa 71024, Estonia

Sanofi-Aventis Investigational Site Number 250204, Amiens Cedex 1 80054, France

Sanofi-Aventis Investigational Site Number 250206, La Rochelle Cedex 17019, France

Sanofi-Aventis Investigational Site Number 250203, Le Creusot 71200, France

Sanofi-Aventis Investigational Site Number 250201, Nantes 44093, France

Sanofi-Aventis Investigational Site Number 250202, Pierre Benite 69310, France

Sanofi-Aventis Investigational Site Number 276201, Dresden 01307, Germany

Sanofi-Aventis Investigational Site Number 276202, Mainz 55116, Germany

Sanofi-Aventis Investigational Site Number 276204, St. Ingbert-Oberwürzbach 66386, Germany

Sanofi-Aventis Investigational Site Number 348205, Balatonfüred 8230, Hungary

Sanofi-Aventis Investigational Site Number 348202, Budapest 1036, Hungary

Sanofi-Aventis Investigational Site Number 348207, Budapest, Hungary

Sanofi-Aventis Investigational Site Number 348204, Debrecen 4031, Hungary

Sanofi-Aventis Investigational Site Number 348206, Gyula 5700, Hungary

Sanofi-Aventis Investigational Site Number 348203, Szeged 6722, Hungary

Sanofi-Aventis Investigational Site Number 348201, Zalaegerszeg 8900, Hungary

Sanofi-Aventis Investigational Site Number 356210, Ahmedabad 380015, India

Sanofi-Aventis Investigational Site Number 356202, Bangalore, India

Sanofi-Aventis Investigational Site Number 356204, Bangalore 560052, India

Sanofi-Aventis Investigational Site Number 356206, Bangalore 560043, India

Sanofi-Aventis Investigational Site Number 356201, Belgaum 590001, India

Sanofi-Aventis Investigational Site Number 356205, Chennai 600086, India

Sanofi-Aventis Investigational Site Number 356208, Indore 452010, India

Sanofi-Aventis Investigational Site Number 356203, Karnal 132001, India

Sanofi-Aventis Investigational Site Number 356207, Kochi, India

Sanofi-Aventis Investigational Site Number 356209, Nagpur 440012, India

Sanofi-Aventis Investigational Site Number 376202, Haifa 31096, Israel

Sanofi-Aventis Investigational Site Number 376201, Holon 58100, Israel

Sanofi-Aventis Investigational Site Number 376204, Kfar Saba 44281, Israel

Sanofi-Aventis Investigational Site Number 376203, Tel Hashomer 52621, Israel

Sanofi-Aventis Investigational Site Number 380201, Milano 20132, Italy

Sanofi-Aventis Investigational Site Number 380202, Perugia 61260, Italy

Sanofi-Aventis Investigational Site Number 458203, Kelantan 16150, Malaysia

Sanofi-Aventis Investigational Site Number 458202, Kuala Lumpur 56000, Malaysia

Sanofi-Aventis Investigational Site Number 484201, Cuernavaca 62250, Mexico

Sanofi-Aventis Investigational Site Number 484204, Durango 34270, Mexico

Sanofi-Aventis Investigational Site Number 484203, Guadalajara 44600, Mexico

Sanofi-Aventis Investigational Site Number 484206, México City 14050, Mexico

Sanofi-Aventis Investigational Site Number 484205, Tlalnepantla 53160, Mexico

Sanofi-Aventis Investigational Site Number 528203, Amsterdam 1066 EC, Netherlands

Sanofi-Aventis Investigational Site Number 528202, Groningen 9728 NT, Netherlands

Sanofi-Aventis Investigational Site Number 528204, Zwijndrecht 3331 LZ, Netherlands

Sanofi-Aventis Investigational Site Number 616202, Krakow 31-548, Poland

Sanofi-Aventis Investigational Site Number 616208, Lubin 59-300, Poland

Sanofi-Aventis Investigational Site Number 616206, Plock 09-400, Poland

Sanofi-Aventis Investigational Site Number 616207, Pulawy 24-100, Poland

Sanofi-Aventis Investigational Site Number 616205, Sopot 81-756, Poland

Sanofi-Aventis Investigational Site Number 616201, Szczecin 70-506, Poland

Sanofi-Aventis Investigational Site Number 616203, Zabrze 41-8--, Poland

Sanofi-Aventis Investigational Site Number 840226, Ponce 00717, Puerto Rico

Sanofi-Aventis Investigational Site Number 840216, San Juan 00917, Puerto Rico

Sanofi-Aventis Investigational Site Number 642204, Brasov 500326, Romania

Sanofi-Aventis Investigational Site Number 642208, Bucharest 020725, Romania

Sanofi-Aventis Investigational Site Number 642205, Deva 330084, Romania

Sanofi-Aventis Investigational Site Number 642203, Iasi 700515, Romania

Sanofi-Aventis Investigational Site Number 642202, Oradea 410598, Romania

Sanofi-Aventis Investigational Site Number 642206, Targu Mures 540061, Romania

Sanofi-Aventis Investigational Site Number 642201, Timisoara 300593, Romania

Sanofi-Aventis Investigational Site Number 642207, Timisoara 300456, Romania

Sanofi-Aventis Investigational Site Number 643203, Saratov 410030, Russian Federation

Sanofi-Aventis Investigational Site Number 643202, St. Petersburg 194358, Russian Federation

Sanofi-Aventis Investigational Site Number 710202, Cape Town 7708, South Africa

Sanofi-Aventis Investigational Site Number 710201, Durban 4092, South Africa

Sanofi-Aventis Investigational Site Number 710203, Pretoria, South Africa

Sanofi-Aventis Investigational Site Number 752204, Göteborg 413 45, Sweden

Sanofi-Aventis Investigational Site Number 752203, Härnösand 871 82, Sweden

Sanofi-Aventis Investigational Site Number 752205, Luleå 972 33, Sweden

Sanofi-Aventis Investigational Site Number 752202, Malmö 211 52, Sweden

Sanofi-Aventis Investigational Site Number 752201, Stockholm 111 57, Sweden

Sanofi-Aventis Investigational Site Number 158204, Changhua 500, Taiwan

Sanofi-Aventis Investigational Site Number 158201, Taichung R.O.C. 407, Taiwan

Sanofi-Aventis Investigational Site Number 158203, Taichung 433, Taiwan

Sanofi-Aventis Investigational Site Number 158202, Tainan Hsien 710, Taiwan

Sanofi-Aventis Investigational Site Number 804203, Chernivtsi 58022, Ukraine

Sanofi-Aventis Investigational Site Number 804201, Kiev 2091, Ukraine

Sanofi-Aventis Investigational Site Number 804202, Kyiv, Ukraine

Sanofi-Aventis Investigational Site Number 804205, Kyiv 31156, Ukraine

Sanofi-Aventis Investigational Site Number 804204, Vinnytsya 21010, Ukraine

Sanofi-Aventis Investigational Site Number 840223, Mesa, Arizona 85206, United States

Sanofi-Aventis Investigational Site Number 840206, Hot Springs, Arkansas 71913, United States

Sanofi-Aventis Investigational Site Number 840201, Little Rock, Arkansas 72205, United States

Sanofi-Aventis Investigational Site Number 840212, Mountain Home, Arkansas 72653, United States

Sanofi-Aventis Investigational Site Number 840215, Concord, California 94520, United States

Sanofi-Aventis Investigational Site Number 840214, Greenbrae, California 94904, United States

Sanofi-Aventis Investigational Site Number 840221, Orlando, Florida 32835, United States

Sanofi-Aventis Investigational Site Number 840211, Baton Rouge, Louisiana 70808, United States

Sanofi-Aventis Investigational Site Number 840230, Hyattsville, Maryland 20781, United States

Sanofi-Aventis Investigational Site Number 840209, Rockville, Maryland 20852, United States

Sanofi-Aventis Investigational Site Number 840219, Brighton, Michigan 48114, United States

Sanofi-Aventis Investigational Site Number 840231, Sea Girt, New Jersey 08750, United States

Sanofi-Aventis Investigational Site Number 840208, Fargo, North Dakota 58103, United States

Sanofi-Aventis Investigational Site Number 840225, Mentor, Ohio 44060, United States

Sanofi-Aventis Investigational Site Number 840222, Portland, Oregon 97201-3098, United States

Sanofi-Aventis Investigational Site Number 840202, Philadelphia, Pennsylvania 19146, United States

Sanofi-Aventis Investigational Site Number 840229, Bristol, Tennessee 37620, United States

Sanofi-Aventis Investigational Site Number 840205, Germantown, Tennessee 38138, United States

Sanofi-Aventis Investigational Site Number 840210, Dallas, Texas 75230, United States

Sanofi-Aventis Investigational Site Number 840217, Houston, Texas 77081, United States

Sanofi-Aventis Investigational Site Number 840228, Houston, Texas 77081, United States

Sanofi-Aventis Investigational Site Number 840213, Plano, Texas 75093, United States

Sanofi-Aventis Investigational Site Number 840227, Norfolk, Virginia 23502, United States

Starting date: October 2009
Last updated: April 9, 2014